The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action

Julio E. Ayala, Deanna P. Bracy, Freyja D. James, Brianna M. Julien, David H. Wasserman, and Daniel J. Drucker

Department of Molecular Physiology and Biophysics (J.E.A., D.P.B., F.D.J., B.M.J., D.H.W.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232; and Department of Medicine (D.J.D.), The Banting and Best Diabetes Centre, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada M5G 1X5

Glucagon-like peptide-1 (GLP-1) diminishes postmeal glucose excursions by enhancing insulin secretion via activation of the β-cell GLP-1 receptor (Glp1r). GLP-1 may also control glucose levels through mechanisms that are independent of this incretin effect. The hyperinsulinemic-euglycemic clamp (insulin clamp) and exercise were used to examine the incretin-independent glucoregulatory properties of the Glp1r because both perturbations stimulate glucose flux independent of insulin secretion. Chow-fed mice with a functional disruption of the Glp1r (Glp1r−/−) were compared with wild-type littermates (Glp1r+/+). Studies were performed on 5-h-fasted mice implanted with arterial and venous catheters for sampling and infusions, respectively. During insulin clamps, [3-3H]glucose and 2[14C]deoxyglucose were used to determine whole-body glucose turnover and glucose metabolic index (Rg), an indicator of glucose uptake. Rg in sedentary and treadmill exercised mice was determined using 2[3H]deoxyglucose. Glp1r−/− mice exhibited increased glucose disappearance, muscle Rg, and muscle glycogen levels during insulin clamps. This was not associated with enhanced muscle insulin signaling. Glp1r−/− mice exhibited impaired suppression of endogenous glucose production and hepatic glycogen accumulation during insulin clamps. This was associated with impaired liver insulin signaling. Glp1r−/− mice became significantly hyperglycemic during exercise. Muscle Rg was normal in exercised Glp1r−/− mice, suggesting that hyperglycemia resulted from an added drive to stimulate glucose production. Muscle AMP-activated protein kinase phosphorylation was higher in exercised Glp1r−/− mice. This was associated with increased relative exercise intensity and decreased exercise endurance. In conclusion, these results show that the endogenous Glp1r regulates hepatic and muscle glucose flux independent of its ability to enhance insulin secretion. (Endocrinology 150: 1155–1164, 2009)
ance, even as arterial insulin and glucose levels were clamped (12). Subsequent studies further suggested that GLP-1 enhances glucose utilization and suppresses hepatic glucose production when insulin and glucagon levels are experimentally controlled (13–19). However, other studies suggest that any glucoregulatory effects of GLP-1 are solely due to its ability to regulate the secretion of pancreatic hormones (20–26). Thus, the notion that GLP-1 can directly regulate glucose production and utilization independent of its effects on the pancreas remains disputed.

The aim of the present studies was to determine whether the endogenous GLP-1 receptor regulates hepatic glucose production and muscle glucose uptake (MGU) independent of its ability to enhance insulin secretion. To this end, the hyperinsulinemic-euglycemic clamp (insulin clamp) and exercise were used to stimulate glucose flux in mice lacking Glp1r expression. Glp1r knockout (Glp1r−/−) mice exhibit oral glucose intolerance and impaired insulin secretion, but basal glucose metabolism is otherwise normal (27, 28). During an insulin clamp, glucose flux is stimulated by experimentally controlled hyperinsulinemia. Conversely, with exercise, glucose flux is stimulated via insulin-independent mechanisms (29). Thus, these two metabolic perturbations were used to reveal glucoregulatory properties of the Glp1r that are both insulin dependent and insulin independent.

Materials and Methods

Mouse maintenance and genotyping

All procedures performed were approved by the Vanderbilt University Animal Care and Use Committee. At 3 wk of age, wild-type (Glp1r+/+) and Glp1r knockout (Glp1r−/−) littermates on the C57BL/6 background were separated by sex and were placed on a standard chow diet (Purina 5001; Purina Mills, St. Louis, MO). Genotyping was performed by PCR on genomic DNA obtained from tail biopsies. All experiments were performed on mice at about 4 months of age. Body composition was determined on 5-h-fasted mice using an mq10 nuclear magnetic resonance analyzer (Bruker Optics, The Woodlands, TX). Mice were maintained on a standard light-dark cycle (0600–1800 h light).

Surgical procedures

Catheters were implanted in the left common carotid artery and right jugular vein for sampling and infusions, respectively, as previously described (30, 31), except surgeries were performed under inhaled anesthesia (VetEquip, Pleasanton, CA). Animals were individually housed after surgery and allowed to recover for 5–7 d, during which time body weight was recorded daily. Mice whose weight did not return to within 10% of presurgery weight were excluded.

Hyperinsulinemic-euglycemic clamps

After 5 d of recovery, insulin clamps were performed on 5-h-fasted mice (30–32). A 5-μCi bolus of [3-3H]glucose was given at t = −90 min before insulin infusion, followed by a 0.05-μCi·min−1 infusion for 90 min. Blood samples were obtained via the arterial catheter (30–32). Basal glucose-specific activity was determined from blood samples at t = −15 and −5 min. Fasting insulin and nonesterified fatty acid (NEFA) levels were determined from blood samples taken at t = −5 min. The clamp was begun at t = 0 min with a continuous infusion of human insulin (4 μU·kg−1·min−1; Humulin R; Eli Lilly, Indianapolis, IN). The [3-3H]glucose infusion was increased to 0.15 μCi·min−1 for the remainder of the experiment. Euglycemia (−150–160 mg·dl−1) was maintained by measuring blood glucose every 10 min starting at t = 0 min and infusing 50% dextrose as necessary. Mice received saline-washed erythrocytes from donors throughout the clamp (5–6 μl·min−1) to prevent a fall of greater than 5% hematocrit. A 12-μCi bolus of 2[14C]deoxyglucose (DG) was given at t = 120 min. Blood samples (80–240 μl) were taken every 10 min from t = 80 to 135 min and processed to determine plasma [3-3H]glucose and 2[14C]DG. Clamp insulin and NEFA was determined at t = 120 min. At t = 135 min, mice were anesthetized with sodium pentobarbital. The soleus, gastrocnemius, superficial vastus lateralis (SVL), liver, diaphragm, heart, and brain were excised, immediately frozen, and stored at −80 C until analyzed. In a separate set of experiments, liver and gastrocnemius from 5-h-fasted mice were excised for determination of basal glycogen content.

Exercise experiments

After 5 d of recovery, mice were acclimated to treadmill running with a single 10-min exercise bout (15.5 m·min−1, 0% grade). Exercise experiments were performed 2 d after this acclimation trial. All exercise experiments were performed on 5-h-fasted mice. One hour before the exercise bout, mice were placed in the treadmill for acclimation. At t = 0 min, an arterial sample (100 μl) was taken for the measurement of baseline blood glucose, hematocrit, and plasma insulin and NEFAs. Mice either remained sedentary or ran on the treadmill for 30 min at 16 m·min−1, 0% grade. This work intensity is about 75% of maximal oxygen consumption in mice (33). Mice were encouraged to run with the use of an electric grid placed at the back end of the treadmill (1.5 mA, 200 msec pulses, 4 Hz). At t = 5 min, a 12-μCi bolus of 2[14C]HG was administered via the jugular vein catheter. At t = 7, 10, 15, and 20 min, arterial samples (−50 μl) were taken to determine blood glucose and plasma 2[14C]HG. At t = 30 min, an arterial sample (150 μl) was taken for the measurement of blood glucose; hematocrit; and plasma insulin, NEFAs, and 2[14C]HG. Mice were then anesthetized and tissues were excised and stored as in clamp experiments.

Exercise stress and exercise endurance testing

Whole-body O2 consumption (VO2) was measured in mice placed in an enclosed treadmill using an Oxymax Deluxe system (Columbus Instruments, Columbus, OH) with an airflow rate of 1 liter·min−1. For exercise stress testing, mice were placed in the enclosed treadmill and allowed to acclimate for at least 30 min. Resting VO2 was determined as the average of measurements over the 10 min before the beginning of the stress test. Mice then began running at 10 m·min−1, 0% grade, and the

<table>
<thead>
<tr>
<th>TABLE 1. Basal (5 h fasted) and insulin clamp characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>n (male/female)</td>
</tr>
<tr>
<td>Weight (g)</td>
</tr>
<tr>
<td>Lean mass (g)</td>
</tr>
<tr>
<td>Fat mass (g)</td>
</tr>
<tr>
<td>Arterial glucose (mg·dl−1)</td>
</tr>
<tr>
<td>Basal</td>
</tr>
<tr>
<td>Insulin clamp</td>
</tr>
<tr>
<td>Insulin (ng·ml−1)</td>
</tr>
<tr>
<td>Basal</td>
</tr>
<tr>
<td>Insulin clamp</td>
</tr>
<tr>
<td>NEFA (nm)</td>
</tr>
<tr>
<td>Basal</td>
</tr>
<tr>
<td>Insulin clamp</td>
</tr>
<tr>
<td>GIR (mg·kg−1·min−1)</td>
</tr>
<tr>
<td>Basal</td>
</tr>
</tbody>
</table>

Basal values represent averages from samples taken at t = −15 and −5 min. Insulin clamp values and GIR represent averages from samples taken at t = 80–120 min. Insulin sensitivity index is calculated as the ratio of GIR to clamp insulin levels. * P < 0.05 vs. Glp1r+/+.
and mice from clamp experiments (insulin clamp, (gastrocnemius) glycogen (D), endoRa (E), and liver glycogen (F) from 5-h-fasted (basal, over the 10 min immediately after exhaustion. Respiratory exchange fraction. Postexercise VO2 was determined as the average of measurements determined as before. Mice were run at 20 m·min⁻¹ until exhausted, with exhaustion defined as before. Exercise VO2 was determined as the average of measurements over the 10 min before exhaustion. Postexercise VO2 was determined as the average of measurements over the 10 min immediately after exhaustion. Respiratory exchange ratio (RER) was calculated as CO2 production/VO2.

Processing of plasma and tissue samples

Insulin levels were determined by ELISA (Linco, St. Charles, MO). NEFAs were measured spectrophotometrically by an enzymatic colorimetric assay (Wako NEFA HR(2) kit; Wako Chemicals, Richmond, VA). Plasma [3-3H]glucose and 2[14C]DG (insulin clamps) or plasma 2[14C]DG (exercise) and tissue 2[14C]DG-6-phosphate 2[14C]DG or tissue 2[14C]DG-6-phosphate (2[H]DGP) radioactivity were determined as previously described (31, 32). The accumulation of 2[14C]DG or 2[14C]DG was normalized to tissue weight. Liver and gastrocnemius glycogen was determined by the method of Chan and Exton (34).

Protein immunoblots

Liver and muscle (gastrocnemius) tissue (20–40 mg) was homogenized in 10 μl·mg⁻¹ tissue extraction buffer [30 mM Tris, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100 (pH 7.5)] supplemented with protease (Pierce, Rockford, IL) and phosphatase (Sigma, St. Louis, MO) inhibitor cocktails. Homogenates were centrifuged (20 min, 4500 × g, 4°C), pellets were discarded, and supernatants were retained for protein determination. Protein content was determined using a BCA protein assay kit (Bio-Rad, Hercules, CA). Whole-cell (20–100 μg) extracts were separated on 10% Bis-Tris SDS-PAGE gels (Invitrogen, Carlsbad, CA), followed by electrophoretic transfer to polyvinylidene fluoride membranes. Primary antibodies were incubated with the membranes overnight at 4°C. Secondary antibodies were incubated at room temperature for 1 h. Imaging and densitometry were performed using the Odyssey imaging system (LiCOR, Lincoln, NE). Antibodies for Akt, phosphorylated Akt (Ser⁴⁷³), glycogen synthase kinase (GSK)-3β, phosphorylated GSK-3β (Ser⁴), total (α/α2) AMP-activated protein kinase (AMPK), and phosphorylated AMPK (Thr¹⁸⁷) were from Cell Signaling (Beverly, MA). Antibody for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Abcam (Berkeley, CA).

Calculations

Whole-body glucose appearance (Rg) and disappearance (Rd) were determined using Steele nonsteady-state equations (35, 36). Endogenous glucose production (endoRg) was determined by subtracting the glucose infusion rate (GIR) from total glucose appearance. Glucose metabolic index (Rg) and glucose clearance (Kg) were calculated as previously described (37, 38) and were normalized to values obtained in the brain.

Statistical analysis

Data are presented as means ± SEM. Differences between groups were determined by one-way ANOVA followed by Tukey’s post hoc tests or by two-tailed t test as appropriate. The significance level was P < 0.05.

Results

Glp1r⁻/⁻ mice exhibit enhanced insulin-stimulated MGU but impaired suppression of endoRg

Baseline characteristics in 5-h-fasted mice undergoing insulin clamps are shown in Table I. Total, fat, and muscle mass was not

FIG. 1. Insulin clamp experiments in 5-h-fasted mice. Arterial glucose (A) and GIR (B) during insulin clamps are presented for Glp1r+/+ (black squares) and Glp1r⁻/⁻ (white squares) mice. Rd (C), muscle glycogen (D), endoRa (E), and liver glycogen (F) from 5-h-fasted (basal, black bars) mice and mice from clamp experiments (insulin clamp, white bars) are presented. Data are mean ± sem for 11–12 mice/genotype. *, P < 0.05 vs. Glp1r+/+; †, P < 0.05 vs. basal within the same genotype.
different between genotypes. There were no differences in fasting glucose, insulin, and NEFA levels among genotypes.

Insulin action was assessed in conscious, unrestrained mice via the insulin clamp. This approach was used to determine the role of the Glp1r in the regulation of hepatic glucose production (endo R_g) and MGU under controlled hyperinsulinemic conditions. Arterial glucose was clamped at similar levels (~150 mg · dl⁻¹) in Glp1r⁺/⁺ and Glp1r⁻/⁻ mice (Fig. 1A). The GIR necessary to maintain euglycemia was significantly higher in which was enhanced in Glp1r expressions. Arterial glucose was clamped at similar levels (Table 1). Clamp insulin and NEFA levels were not different between genotypes (Table 1). Normalizing the GIR to clamp insulin levels, an index of whole-body insulin sensitivity, shows that disruption of Glp1r expression results in enhanced insulin-stimulated MGU and muscle glyco-
gen accumulation but impaired suppression of endogenous glucose production and hepatic glycogen accumulation.

**Disruption of Glp1r expression does not enhance muscle insulin signaling but does impair hepatic insulin signaling**

To determine whether increased muscle R_g in Glp1r⁻/⁻ mice was due to enhanced insulin action, activation of insulin signaling proteins was assessed (Fig. 3). Disruption of Glp1r expression did not increase levels of phosphorylated or total Akt in muscle (Fig. 3B). Thus, activation of muscle Akt, defined as the ratio of phosphorylated to total Akt, was not different between genotypes (Fig. 3C). Phosphorylation of muscle GSK-3β, which inactivates this enzyme and promotes glycogen synthesis, was also not affected by the lack of Glp1r expression (Fig. 3, B and C). These results show that increased muscle R_g and muscle glycogen accumulation in Glp1r⁻/⁻ mice is not associated with enhanced insulin signaling.

In contrast with muscle phenotypes, the inability of insulin to completely suppress endoR_g in Glp1r⁻/⁻ mice does correlate with impaired hepatic insulin signaling. Although Akt activation was not different between genotypes, levels of phosphorylated and total Akt were decreased in Glp1r⁻/⁻ mice (Fig. 3, E and F). Furthermore, decreased hepatic glycogen accumulation in Glp1r⁻/⁻ mice was associated with decreased phosphorylation of GSK-3β (Fig. 3, E and F).

**Glp1r⁻/⁻ mice exhibit hyperglycemia during exercise even as MGU is normal**

Exercise stimulates glucose flux in the absence of an increase in insulin levels. This physiological intervention was used to further characterize the glucoregulatory properties of the Glp1r that are independent of its ability to stimulate insulin secretion. During moderate exercise, increased glucose use by the working muscle is typically matched by an increase in hepatic glucose production (29). The consequence of this is that arterial glucose levels do not vary appreciably during exercise, as was observed in Glp1r⁺/⁺ mice (Fig. 4A). Such was not the case in Glp1r⁻/⁻ mice, which exhibited exercise-induced hyperglycemia (Fig. 4A). This could not be attributed to an effect on the dynamics of insulin because both genotypes showed a similar decrease in the levels of this hormone (Fig. 4B). Plasma NEFA levels were not different between the genotypes in sedentary or exercised mice (Fig. 4C). Similarly, muscle and liver glycogen levels were not different between genotypes in either sedentary or exercised mice (Fig. 4, D and E).

To assess whether exercise-induced hyperglycemia in Glp1r⁻/⁻ mice was due to a defect in MGU, R_g was measured in various muscle types (Fig. 5). R_g in hindlimb skeletal muscles was not different between genotypes in sedentary mice and was equally increased in response to exercise (Fig. 5, A–C). Whereas R_g in the diaphragm did not increase with exercise in Glp1r⁺/⁺ mice, it was significantly increased in Glp1r⁻/⁻ mice (Fig. 5D). Conversely, R_g in the heart was stimulated by exercise in Glp1r⁺/⁺ mice but was unaffected in Glp1r⁻/⁻ mice (Fig. 5E). This likely is due to the fact that sedentary R_g in the heart was elevated in Glp1r⁻/⁻ mice, such that exercise did not increase it further.
results of exercise studies show that exercise-induced hyperglycemia-stimulated Kg in the diaphragm and sedentary Kg in the heart in sedentary and exercised mice (Fig. 5, F–H). Furthermore, exercise-stimulated AMPK activation (P-Akt/Akt) and GSK-3β inactivation (P-GSK-3β/GSK-3β) were elevated in Glp1r−/− mice, whereas Glp1r+/+ mice exhibited hyperglycemia during exercise (37). Because glucose levels were higher in Glp1r−/− mice but about 88% of VO2,max in Glp1r−/− mice. This shows that at a given absolute work intensity, Glp1r−/− mice exercise at a higher relative intensity. This was associated with a decrease in endurance capacity, measured as time to exhaustion during treadmill exercise at 20 m · min⁻¹ (Table 2).

Glp1r−/− mice exercise at a relatively higher intensity and have impaired exercise endurance

High intensity exercise is characterized by increased arterial glucose levels and enhanced skeletal muscle AMPK activation (29, 42, 43). To assess whether Glp1r−/− mice exercise at different relative intensities for a given treadmill speed, exercise stress and exercise endurance tests were performed. Capacity for maximum intensity exercise was not different between the two genotypes, as noted by the running rates during an exercise stress test. However, VO2,max was significantly higher in Glp1r−/− mice (Table 2). During an exercise endurance test, mice from both genotypes ran at the same absolute speed (20 m · min⁻¹). As shown in Table 2, this work intensity corresponded to about 78% of VO2,max in Glp1r−/− mice but about 88% of VO2,max in Glp1r−/− mice. This shows that at a given absolute work intensity, Glp1r−/− mice exercise at a higher relative intensity. This was associated with a decrease in endurance capacity, measured as time to exhaustion during treadmill exercise at 20 m · min⁻¹ (Table 2).

Discussion

The role of the Glp1r to enhance insulin secretion in response to nutrient intake has been clearly established. It was thus assumed that this incretin action mediated through the β-cell was solely responsible for any effects of Glp1r activation on hepatic glucose production and MGU. Whereas it has been proposed that the Glp1r can regulate glucose production and utilization independent of its effect on pancreatic hormone secretion (13–19), this idea remains controversial (20–26). In the present study, insulin clamp experiments were used to stimulate glucose flux under conditions in which circulating insulin levels were experimentally controlled (insulin clamps) or decreased (exercise). This approach was taken to assess the potential role of the Glp1r to regulate MGU independent of its ability to stimulate endogenous insulin secretion. Given its role in mediating the incretin effect, it was surprising to observe that Glp1r−/− mice exhibited enhanced skeletal muscle glucose uptake during an insulin clamp. Conversely, suppression of hepatic glucose production was impaired in these mice. These effects were paralleled by increased muscle glycogen accumulation and decreased hepatic glycogen accumulation. In response to exercise, Glp1r−/− mice became impaired in these mice. These effects were paralleled by increased muscle glycogen accumulation and decreased hepatic glycogen accumulation. In response to exercise, Glp1r−/− mice became
hypercglycemic. This was not due to a defect in glucose uptake as MGU was normal or increased in Glp1r+/- mice. Taken together, these results demonstrate that, under conditions of increased glucose flux, the endogenous Glp1r is a regulator of glucose production and MGU independent of its ability to stimulate endogenous insulin secretion.

We have previously shown that disruption of both the Glp1r and the Gipr in double-incretin receptor knockout (DIRKO) mice preserves insulin action in response to chronic high-fat feeding, a dietary intervention that precipitates insulin resistance in C57BL/6 mice (32). DIRKO mice are also protected from high-fat diet-induced obesity due to increased energy expenditure (32, 44). Disruption of the Gipr increases fat oxidation and decreases adiposity in genetic and dietary rodent models of obesity (45–47). This results in improved glucose tolerance and insulin sensitivity (45–48). Thus, the enhanced insulin action in DIRKO mice is likely due, at least in part, to the improved metabolic profile resulting from the loss of Gipr expression. In the present studies, we show that fat mass and muscle mass is normal in Glp1r+/- mice. Therefore, the phenotypes observed in Glp1r+/- mice are not secondary to an effect on body composition.

Our findings from insulin clamp and exercise studies reveal a novel role for the Glp1r in the regulation of hepatic glucose production and MGU during conditions of increased glucose flux. A direct effect of GLP-1 on the liver and muscle is not likely because neither tissue expresses the Glp1r. Recent evidence indicates that Glp1r action in the brain, particularly in the hypothalamus, can acutely regulate glucose production and use. Knauf et al. (49) showed that glucose requirements during a hyperinsulminemic-hyperglycemic clamp were higher in Glp1r+/- mice and mice receiving an intracerebroventricular infusion of the Glp1r antagonist exendin (9–39). Furthermore, hepatic glycogen levels were lower, whereas muscle glycogen levels were higher, in Glp1r+/- mice and mice receiving intracerebroventricular infusions of exendin (9–39). A similar phenotype was observed in the present studies using Glp1r+/- mice and was associated with impaired suppression of endoRo but enhanced MGU. The effect of central Glp1rs to regulate hepatic and muscle insulin action appears to be limited to receptors in the arcuate nucleus of the hypothalamus. Infusion of GLP-1 into the arcuate nucleus, but not the paraventricular nucleus, has recently been shown to enhance suppression of endoRo but impair stimulation of Rdl during insulin clamps in rats (50). This is in agreement with the present studies, which show that disruption of Glp1r expression impairs suppression of endoRo but enhances stimulation of Rd.

Enhanced insulin-stimulated MGU and muscle glycogen accumulation in Glp1r+/- mice was not associated with increased activation of insulin signaling proteins. This is also consistent with the findings of Knauf et al. (49), who showed that increased muscle glycogen accumulation via inhibition of central Glp1rs does not require expression of the insulin receptor in muscle. This effect of central Glp1r action did require innervation of the muscle because severing of the sciatic nerve blunted muscle glycogen accumulation (49). Contrasting the effects observed in the muscle, the hepatic phenotypes observed in Glp1r+/- mice were associated with an effect on insulin signaling. Thus, the impaired ability of insulin to suppress endoRm in Glp1r+/- mice correlated with decreased levels of total and phosphorylated Akt. Furthermore, decreased hepatic glycogen storage in these mice was associated with decreased phosphorylation of GSK-3β.

We next addressed whether the Glp1r regulates MGU in the absence of an increase in insulin levels. Exercise is a useful tool to address this question because it stimulates MGU via insulin-independent mechanisms. Whereas arterial glucose levels did not vary appreciably during exercise in Glp1r+/+ mice, Glp1r+/- mice exhibited exercise-induced hyperglycemia. This was not due to an impairment in MGU, which was normal in hindlimb
The phenotype observed in Glp1r^-/- mice typically increases to match glucose use by the contracting muscle. During moderate exercise, hepatic glucose production results from an inappropriate increase in hepatic glucose production during insulin clamps makes physiologic sense. Such a role for the Glp1r during exercise is less clear because exercise is characterized by an increase in hepatic glucose production, and activation of Glp1r would counter this hepatic response. Venous levels of GLP-1 increase with exercise (51), raising the possibility that activation of the Glp1r is involved in the normal response to exercise.

Glucagon is a major driving force behind the increase in endoRa during exercise (52). Because activation of the Glp1r suppresses glucagon secretion (8, 9, 11), it is possible that increased hepatic glucose production in Glp1r^-/- mice during insulin clamps and exercise results from increased glucagon secretion. Previous studies have shown normal fasting glucagon levels, as well as normal suppression of glucagon by oral glucose loading, in Glp1r^-/- mice (27, 53, 54). However, these measurements of plasma glucagon were made from cardiac blood samples. Because glucose clearance occurs in the liver, portal vein glucagon levels would more accurately represent changes in the secretion of this hormone. Thus, it is still possible that increased glucagon secretion plays a role in the hepatic phenotypes observed in the present studies.

Activation of muscle AMPK has been implicated as necessary for the increase in MGU during exercise (39–41). Interestingly, phosphorylation of muscle AMPK, a marker of activation, was significantly inhibited in Glp1r^-/- mice compared to Glp1r^+/+ mice (27, 53, 54). Studies have shown normal contraction-induced stimulation of MGU in the absence of functional increases in AMPK activity (55–58). Activation of muscle AMPK increases with exercise intensity (42, 43). Results from maximal and endurance exercise tests performed in the present studies suggest that for the same absolute speed, Glp1r^-/- mice exercise at a greater intensity than Glp1r^+/+ mice. Thus, at a speed of 20 m · min^-1, the speed used in endurance tests in the present studies, Glp1r^+/+ mice were exercising at about 78% of their VO2,max whereas Glp1r^-/- mice were exercising at about 88% of their VO2,max. This was...
function (59). Activation of central Glp1rs increases heart rate and blood pressure (60, 61). Recent studies also demonstrate a protective role for the Glp1r against cardiac injury and heart failure (62–68). Disruption of Glp1r expression results in defects in cardiac morphology and function, including increased left ventricular thickness and impaired left ventricular contractility (69). These cardiac phenotypes are often associated with a preference for glucose over fatty acid oxidation in the heart (70–72). In support of this, sedentary cardiac glucose uptake was increased in Glp1r-/- mice in the present studies. It is thus possible that these phenotypes associated with impaired cardiac function explain the decreased exercise capacity in Glp1r-/- mice.

In conclusion, the present studies show that the Glp1r regulates glucose production and use independent of its ability to stimulate insulin secretion. The findings from the insulin clamp studies suggest an important role for the Glp1r in the proper disposal of meal-derived glucose. By enhancing hepatic insulin action at the expense of MGU, activation of Glp1rs ensures that hepatic glucose clearance is increased and hepatic glycogen stores are replenished. This is crucial for the maintenance of glucose homeostasis during the postabsorptive period. Results from exercise studies suggest that activation of Glp1rs also occurs during exercise. Although endoRa was not directly measured, the fact that glucose levels rose during exercise in Glp1r-/- mice in the absence of a defect in MGU suggests an increase in glucose production exceeding the rate of use. This demonstrates a role for the Glp1r in the regulation of glucose production independent of insulin.

Taken together, these results extend the importance of GLP-1 action in regulating glucose homeostasis beyond the pancreas and show it to be a key determinant of glucose fate during times of increased flux.

Acknowledgments

We thank Dr. Owen McGuinness, Carlo Malabanan, and Tasneem Ansari (Vanderbilt Mouse Metabolic Phenotyping Center Metabolic Pathophysiology Core) for body composition and exercise endurance analysis.

Address all correspondence and requests for reprints to: Julio E. Ayala, Ph.D., 2200 Pierce Avenue, 702 Light Hall, Nashville, Tennessee 37232. E-mail: julio.ayala@vanderbilt.edu.

This work was supported by National Institutes of Health Grants R01 DK-50277 (to D.H.W.) and U24 DK-59637 (to the Vanderbilt Mouse Metabolic Phenotyping Center) and Juvenile Diabetes Research Foundation Grant 1-2006-796 (to D.J.D.).

Disclosure Statement: All of the authors have nothing to disclose.

TABLE 2. Results from exercise stress and exercise endurance tests

<table>
<thead>
<tr>
<th>Glp1r+/+</th>
<th>Glp1r-/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (male/female)</td>
<td>14 (9/5)</td>
</tr>
<tr>
<td>Maximum running rate (m·min⁻¹)</td>
<td>36.3 ± 1.3</td>
</tr>
<tr>
<td>VO2max (ml·kg⁻¹·min⁻¹)</td>
<td>132 ± 4</td>
</tr>
<tr>
<td>Endurance time (min)</td>
<td>120 ± 13</td>
</tr>
<tr>
<td>VO2 (ml·kg⁻¹·min⁻¹)</td>
<td>90 ± 5</td>
</tr>
<tr>
<td>Rest</td>
<td>103 ± 3</td>
</tr>
<tr>
<td>Exercise</td>
<td>61 ± 5</td>
</tr>
<tr>
<td>After exercise</td>
<td>0.75 ± 0.04</td>
</tr>
<tr>
<td>RER</td>
<td>0.77 ± 0.03</td>
</tr>
<tr>
<td>Exercise</td>
<td>0.70 ± 0.02</td>
</tr>
</tbody>
</table>

Maximum running rate and VO2max were determined from exercise stress tests. Endurance time VO2 and RER were determined from exercise endurance tests.

* P < 0.05 vs. Glp1r+/+.
References

41. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR 2007 Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin
resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50:1752–1762


64. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM 2005 Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetologia 54:146–151

65. Bose AK, Mocanu MM, Carr RD, Yellon DM 2005 Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19:9–11


69. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M 2003 Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144:2242–2252

70. Opie LH 1968 Metabolism of the heart in health and disease. I. Am Heart J 76:685–698
